"The Federal Trade Commission has ordered Illumina to divest cancer screening company Grail, arguing the $8bn acquisition would damage competition in the US market for life-saving cancer tests."

https://www.ft.com/content/3848cf02-8d00-4286-ab96-f3d72bde3c8e